Management of Heart Failure in Patients With Type 2 Diabetes

Deepak L. Bhatt, MD, MPH


February 06, 2023

Type 2 diabetes (T2D) and heart failure (HF) are rapidly increasing in the US population and often coexist. The American Heart Association, the American College of Cardiology, and the Heart Failure Society of America have released guidelines recommending sodium-glucose cotransporter 2 (SGLT2) inhibitors, which are considered antidiabetic drugs, as first-line treatment for heart failure regardless of T2D diagnosis, unless contraindicated.

Large-scale clinical trials, such as EMPA-REG, demonstrated a reduction in HF hospitalization and cardiovascular mortality compared with placebo. CANVAS and DECLARE-TIMI 58 further demonstrated the benefits of SGLT2 inhibitors in an HF population. Additional clinical trials, such as SCORED, EMPA-KIDNEY, and SOLOIST, are examining benefit of SGLT2 inhibitors in this patient population with comorbidities.

Dr Deepak Bhatt of Icahn School of Medicine at Mount Sinai Health System discusses the emerging clinical data establishing SGLT2 inhibitors as valuable, but frequently underprescribed, in the management of heart failure patients with T2D.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.